Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry-Reference-Cited by-同舟云学术

Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry

Published:2020-11 Issue:5 Volume:83 Page:1375-1384
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Bosma Angela L.,de Wijs Linde E.M.,Hof Michel H.,van Nieuwenhuizen Beau R.,Gerbens Louise A.A.,Middelkamp-Hup Maritza A.,Hijnen DirkJan,Spuls Phyllis I.

Funder

ZonMw

Publisher

Elsevier BV

Subject

Dermatology

Reference27 articles.

1. The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada;de Bruin-Weller;J Eur Acad Dermatol Venereol,2020

2. Severity distribution of atopic dermatitis in the community and its relationship to secondary referral;Emerson;Br J Dermatol,1998

3. What's new in atopic eczema? An analysis of systematic reviews published in 2017. Part 1: treatment and prevention;Wernham;Clin Exp Dermatol,2019

4. Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data;de Wijs;Br J Dermatol,2020

5. Introduction of dupilumab for severe constitutional eczema [in Dutch];Schuttelaar;Ned Tijdschr Dermatol Venereol,2018

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Higher prevalence of dupilumab‐induced ocular adverse events in atopic dermatitis compared to asthma: A daily practice analysis;Clinical and Translational Allergy;2024-08

2. Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry;Journal of the American Academy of Dermatology;2024-08

3. Efficacy and tolerance of dupilumab in patients with moderate‐to‐severe atopic dermatitis and obesity;Journal of the European Academy of Dermatology and Venereology;2024-07-31

4. Dupilumab-associated (hyper)eosinophilia in patients with atopic dermatitis: a single-centre cohort study of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry;British Journal of Dermatology;2024-07-15

5. Efficacy and Safety of Dupilumab for the Treatment of Severe Atopic Dermatitis in Clinical Practice: A Single Center Experience;Actas Dermo-Sifiliográficas;2024-02